MANDATORY NOTIFICATION OF TRADE

DiaGenic today announce mandatory notification of trades among primary insiders of DiaGenic ASA which took place as part of the allotment of shares in the “Subsequent offering”. Reference is made to the notice to the stock exchange on 9 February 2010 regarding notification of trades among primary insiders which subscribed in the “Subsequent offering”, and the notice to the stock exchange on 15 February 2010 regarding allotment of shares in the “Subsequent offering”. The transactions are described in detail below. Håkon Sæterøy, Executive Chairman of the Board of DiaGenic ASA, has through his companies Investor Corporate AS and Investor Partners AS been allotted 74,801 shares at NOK 2.75 per share and 74,801 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Investor Corporate AS, owned 100% by Sæterøy, today sold 292,611 shares in DiaGenic at NOK 3 per share. The shares were bought by ISB Invest AS (97 537 shares) and Gezina AS (195 074 shares) as a settlement of seller’s credit in the amount of NOK 2.6 million in connection with Håkon Sæterøy’s purchase of shares in Investor Corporate AS from the above mentioned companies in September 2005. Sæterøy’s overall exposure in the Company is 1,178,668 shares after the transactions mentioned above, in addition to 229,801 warrants, and in addition to the TRS agreement with exposure for 135,000 shares. Gustav Ingemar Kihlström, Deputy Chairman of the Board of DiaGenic ASA, was allotted 8,956 shares at NOK 2.75 per share and 8,956 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Kihlström`s overall exposure in the Company has increased to a total of 113,956 shares and 8,956 warrants. CEO Erik Christensen was allotted 13,000, shares at NOK 2.75 per share and 13,000 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Christensen overall exposure in the Company has increased to a total of 103,000 shares and 13,000 warrants in addition to a TRS agreement with exposure for 60,000 shares. Praveen Sharma, Director and board member in DiaGenic ASA, was allotted 195,764 shares at NOK 2.75 per share and 195,764 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Sharma’s overall exposure in the Company has increased to a total of 2,490,764 shares and 195,764 warrants in addition to the TRS agreement with exposure for 700,000 shares. Anders Lönneborg, Director in DiaGenic ASA, was allotted 7,370 shares at NOK 2.75 per share and 7,370 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Lönneborg’s overall exposure in the Company has increased to a total of 2,907,370 shares and 7,370. Morten Sten Johansen, Director in DiaGenic ASA, was allotted 20,000 shares at NOK 2.75 per share and 20,000 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Johansen’s overall exposure in the Company has increased to a total of 160,000 shares and 20,000 warrants. Dag Christian Christiansen, Director in DiaGenic ASA, was allotted 10,000 shares at NOK 2.75 per share and 10,000 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Christiansen’s overall exposure in the Company has increased to a total of 260,000 shares and 10,000 warrants. Maria Holmlund, board member in DiaGenic ASA, was allotted 1,000 shares at NOK 2.75 per share and 1,000 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Holmlund’s overall exposure in the Company has increased to a total of 11,000 shares and 1,000 warrants. Ingrid Alfheim, board member in DiaGenic ASA, was allotted 1,295 shares at NOK 2.75 per share and 1,295 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Alfheim’s overall exposure in the Company has increased to a total of 7,840 shares and 1,295 warrants. Torbjørn Lindahl, head of bioinformatics and IT in DiaGenic ASA, was allotted 3,500 shares at NOK 2.75 per share and 3,500 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Lindahl’s overall exposure in the Company has increased to a total of 38,500 shares and 3,500 warrants. Ruben Ekbråten, Financial Controller in DiaGenic ASA, was allotted 1,981 shares at NOK 2.75 per share and 1,981 warrants in the “Subsequent offering”. The subscription price for the warrants is set to NOK 3.25 per share and the term expires on 30 September 2010. Ekbråten’s overall exposure in the Company has increased to a total of 11,981 shares and 1,981 warrants. Contact: MD PhD Erik Christensen, CEO Telephone: +47 95939918 e-mail: erik.christensen@diagenic.com